NCT05217771

Brief Summary

The Coronavirus Disease 2019 (COVID-19) is a highly transmittable and pathogenic viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2), which emerged in Wuhan, China in December 2019 and its spread around the world has been rapid (Rathi et al., 2021; Vakili et al., 2021). COVID-19 impacts on economy, society, education , neurological, psychiatric and psychosocial impairments , increasing the burden of disease and disability throughout the world have been studied by several authors (Phillips et al., 2020; Pragholapati, 2020). COVID-19 may lead to greater risks of long-term scarring, permanently lower economic activity, a significant increase in the prevalence of chronic illness, social distancing, isolation, changes in teaching and learning strategies to decrease of number of days of education, the number of social contacts each day is limited (Minister \& Majesty, 2020; Almomani et al., 2021) .

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 10, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 24, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 1, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2022

Completed
Last Updated

February 1, 2022

Status Verified

January 1, 2022

Enrollment Period

1 year

First QC Date

January 24, 2022

Last Update Submit

January 28, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Six-Minute Walk Test

    for functional capacity

    4 weeks

  • Chalder Fatigue Scale: score can range from 0 to 33, with a higher score indicating greater fatigue.

    for chronic Fatigue

    4 weeks

Study Arms (2)

High tone power therapy group

EXPERIMENTAL

patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.

Other: High tone power therapy group

control group

EXPERIMENTAL

Patients in control group will receive high tone sham therapy 3 times per week and self-stretch for hand and shoulder.

Other: High tone power therapy group

Interventions

patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.

High tone power therapy groupcontrol group

Eligibility Criteria

Age40 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • All patients were diagnosed with COVID-19 by polymerase chain reaction (PCR) test of a nasopharyngeal sample during acute phase, completed CBC, lymphocyte inflammatory marker, c-reactive protein and ESR.
  • Patients must be negative polymerase chain reaction (PCR).
  • Patients will be completely recovered from acute symptoms of covid-19.
  • Patients will be recruited after 2- 4 weeks post complete recovery from acute symptoms

You may not qualify if:

  • Patients with feverish systemic or local bacterial infections.
  • Epilepsy.
  • Pregnant women patients.
  • Cancer.
  • Uncontrolled Diabetes milletus \>250 mg/dl

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emad

Cairo, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer assistant

Study Record Dates

First Submitted

January 24, 2022

First Posted

February 1, 2022

Study Start

November 10, 2021

Primary Completion

November 20, 2022

Study Completion

November 20, 2022

Last Updated

February 1, 2022

Record last verified: 2022-01

Locations